{"id":"arm-b-rituxan-mabthera","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"10-30","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3896316","moleculeType":"Small molecule","molecularWeight":"654.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers immune-mediated destruction of B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This B cell depletion reduces autoimmune and malignant B cell populations.","oneSentence":"Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:19.956Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma (B-cell)"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT05952024","phase":"PHASE2","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT04833114","phase":"PHASE3","title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-04-30","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":306},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT01796171","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Nordic Nanovector","startDate":"2012-12","conditions":"Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":191},{"nctId":"NCT06205290","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-16","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT02012088","phase":"PHASE2","title":"Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2013-10-11","conditions":"Lymphoma","enrollment":91},{"nctId":"NCT03976102","phase":"PHASE3","title":"Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2019-05-15","conditions":"Follicular Lymphoma","enrollment":317},{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Relapsed Follicular Lymphoma","enrollment":159},{"nctId":"NCT02733042","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-11","conditions":"Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":106},{"nctId":"NCT04268771","phase":"PHASE3","title":"A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2020-04-08","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT01216683","phase":"PHASE2","title":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-09","conditions":"Lymphoma","enrollment":289},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT01939327","phase":"PHASE2","title":"Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2013-09","conditions":"Non-Hodgkin Lymphoma","enrollment":34},{"nctId":"NCT02366663","phase":"PHASE3","title":"BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2015-01","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT00816595","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-02","conditions":"Leukemia, Lymphoma","enrollment":68},{"nctId":"NCT01556035","phase":"PHASE2","title":"Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2012-07","conditions":"Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)","enrollment":19},{"nctId":"NCT02531841","phase":"PHASE3","title":"High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"University Hospital Freiburg","startDate":"2014-07","conditions":"Diffuse Large B-cell-lymphoma","enrollment":250},{"nctId":"NCT00628238","phase":"PHASE2","title":"Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)","status":"UNKNOWN","sponsor":"Chronic Lymphocytic Leukemia Research Consortium","startDate":"2008-02","conditions":"Chronic Lymphocytic Leukemia, CLL, Untreated","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Arm B: Rituxan®/Mabthera®","genericName":"Arm B: Rituxan®/Mabthera®","companyName":"Dr. Reddy's Laboratories Limited","companyId":"dr-reddy-s-laboratories-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}